PD‐L1, a ligand for the co‐inhibitory receptor PD‐1, is expressed on various cells, especially tumor cells.[3] The PD‐L1/PD‐1 interaction inhibits T‐cell proliferation, survival, and cytokine secretion as well as promotes T‐cell exhaustion, making it a key player in T‐cell suppression and a prominent target for antitumor immunotherapy, including in HCC.[3, 33] Transcription factors are one of the major regulators of PD‐L1 abnormal expression in tumors. Here, CD274 is linked to hepatocellular carcinoma.